{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:50:05Z","timestamp":1762674605063,"version":"3.37.3"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Astellas Pharma France"},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Limited real-world data are available in Europe, especially France, regarding the therapeutic management of anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective, longitudinal, observational study was based on medical records from the MEDIAL database of not-for-profit dialysis units in France. From January to December 2016, we included eligible patients (\u226518 years), with a diagnosis of CKD and receiving maintenance dialysis. Patients with anaemia were followed up for 2 years after inclusion. Patient demographic data, anaemia status, CKD-related anaemia treatments, and treatment outcomes including laboratory test results were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1632 DD CKD patients identified from the MEDIAL database, 1286 had anaemia; 98.2% of patients with anaemia were receiving haemodialysis at index date (ID). Of patients with anaemia, 29.9% had haemoglobin (Hb) levels of 10\u201311\u00a0g\/dL and 36.2% had levels of 11\u201312\u00a0g\/dL at ID. Furthermore, 21.3% had functional iron deficiency and 11.7% had absolute iron deficiency. The most commonly prescribed treatments at ID for patients with DD CKD\u2013related anaemia were intravenous (IV) iron with erythropoietin-stimulating agents (ESAs) (65.1%). Among patients initiating ESA treatment at ID or during follow-up, 347 (95.3%) reached the Hb target of 10\u201313\u00a0g\/dL and maintained response within the target Hb range for a median duration of 113 days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite combined use of ESAs and IV iron, duration within the Hb target range was short, suggesting that anaemia management can be further improved.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ckj\/sfac245","type":"journal-article","created":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T22:12:09Z","timestamp":1667254329000},"page":"501-511","source":"Crossref","is-referenced-by-count":3,"title":["Management of anaemia in French dialysis patients: results from a large epidemiological retrospective study"],"prefix":"10.1093","volume":"16","author":[{"given":"Philippe","family":"Zaoui","sequence":"first","affiliation":[{"name":"CHU Grenoble-Alpes & AGDUC , Grenoble, Is\u00e8re , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile","family":"Courivaud","sequence":"additional","affiliation":[{"name":"CHU Besan\u00e7on , Besan\u00e7on, Doubs , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Rostoker","sequence":"additional","affiliation":[{"name":"H\u00f4pital Priv\u00e9 Claude Galien, Ramsay-G\u00e9n\u00e9rale de Sant\u00e9 , Quincy sous S\u00e9nart, Essonne , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Choukroun","sequence":"additional","affiliation":[{"name":"Nephrology Dialysis Transplantation Department, CHU Amiens and MP3CV Research Unit, Universit\u00e9 de Picardie Jules Verne , Amiens , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Dubel","sequence":"additional","affiliation":[{"name":"Astellas Pharma France , Levallois-Perret , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe Ltd , Addlestone, Surrey , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Harmand","sequence":"additional","affiliation":[{"name":"IQVIA , La D\u00e9fense, Hauts-de-Seine , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victorio","family":"Menoyo Calonge","sequence":"additional","affiliation":[{"name":"Association ECHO , Nantes, Loire-Atlantique , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"2023022812303680700_","first-page":"279","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ckj\/sfaa054","article-title":"Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis","volume":"13","author":"Evans","year":"2020","journal-title":"Clin Kidney J"},{"key":"2023022812303680700_","first-page":"8","article-title":"Anemia of chronic kidney disease: protocol of study, management and referral to","volume":"38","author":"Cases","year":"2018","journal-title":"Nephrology. Nefrolgia (Engl Ed)"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1038\/ki.2008.523","article-title":"Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality","volume":"111","author":"L\u00f3pez-G\u00f3mez","year":"2008","journal-title":"Kidney Int Suppl"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ki.2011.179","article-title":"Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease","volume":"80","author":"Bamgbola","year":"2011","journal-title":"Kidney Int"},{"article-title":"R\u00e9sultats des indicateurs pour l'am\u00e9lioration de la qualit\u00e9 et de la s\u00e9curit\u00e9 des soins","year":"2017","author":"Haute Authorit\u00e9 de Sant\u00e9 (HAS)","key":"2023022812303680700_"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"i16","DOI":"10.1093\/ckj\/sfx043","article-title":"Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions","volume":"10","author":"Macdougall","year":"2017","journal-title":"Clin Kidney J"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2215\/CJN.01070308","article-title":"Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation","volume":"3","author":"Rambod","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1046\/j.1523-1755.61.s80.11.x","article-title":"Darbepoetin alfa: a new therapeutic agent for renal anemia","volume":"80","author":"Macdougall","year":"2002","journal-title":"Kidney Int Suppl"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/ndt\/18.3.576","article-title":"Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis","volume":"18","author":"Macdougall","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2023022812303680700_","first-page":"136","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2023022812303680700_","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","article-title":"Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis","volume":"61","author":"Koulouridis","year":"2013","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfac245\/48437660\/sfac245.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/3\/501\/49352017\/sfac245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/16\/3\/501\/49352017\/sfac245.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T20:36:04Z","timestamp":1678480564000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/16\/3\/501\/6794269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,11,2]]},"published-print":{"date-parts":[[2023,2,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfac245","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"type":"print","value":"2048-8505"},{"type":"electronic","value":"2048-8513"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2022,11,2]]}}}